{
    "2021-12-10": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Novartis data highlight efficacy of PiqrayÂ® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Piqray",
                        "HR+/HER2-",
                        "metastatic breast cancer",
                        "PIK3CA",
                        "efficacy",
                        "CDK4/6i"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis CEO says Sandoz attracting interest - paper",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "Sandoz",
                        "attracting interest"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}